TORONTO, December 10 /CNW/ - Biovail Corporation (NYSE: BVF)(TSX:BVF)
today announced that Canadian pharmaceutical industry veteran Lloyd M. Segal,
Chief Executive Officer of Thallion Pharmaceuticals Inc. of Montreal, has been
appointed to Biovail's Board of Directors.
Mr. Segal's appointment is effective immediately.
"We're delighted to welcome Lloyd Segal to Biovail's Board of Directors,"
said Dr. Douglas Squires, Interim Chairman of the Board and the Company's CEO.
"Mr. Segal's appointment provides pharmaceutical industry expertise upon which
both the Board, and the Company's management team, can draw as Biovail moves
through the next phase of its development."
Mr. Segal served as President and CEO of Caprion Pharmaceuticals of
Montreal from 1998 until its merger earlier this year with Ecopia BioSciences
to form Thallion Pharmaceutials, a biotechnology company focused on the
development of new treatments for underserved markets in the areas of oncology
and infectious disease. He was previously a management consultant with
McKinsey & Co., and President and CEO of Advanced Bioconcept Ltd., which was
sold to NEN Life Sciences (now Perkin-Elmer) in 1998.
Mr. Segal is currently a member of the Board of Directors at GBC North
American Growth Fund, Inc., one of Canada's leading growth-oriented mutual
funds. He is also a member of the Brandeis University Science Advisory
Council. Previously, Mr. Segal was a member of the Board of Directors of
BIOTECanada, Canada's national biotechnology industry association. He has also
served on the boards of both TSX and NASDAQ-listed public companies, and
privately held companies in the health-care industry.
Mr. Segal received his Masters Degree in Business Administration from
Harvard Business School in Cambridge, MA. He also holds a Bachelor of Arts
degree in Politics from Brandeis University in Waltham, MA.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company, engaged in the
formulation, clinical testing, registration, manufacture, and
commercialization of pharmaceutical products utilizing advanced drug-delivery
technologies. For more information about Biovail, visit the Company's Web site
For further information, please contact Nelson F. Isabel at 905-286-3000
or send inquiries to firstname.lastname@example.org.
For further information:
For further information: Biovail Corporation Nelson F. Isabel,
905-286-3000 Vice-President, Investor Relations and Corporate Communications